5OGR

Structure of cathepsin B1 from Schistosoma mansoni in complex with WRR286 inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.55 Å
  • R-Value Free: 0.203 
  • R-Value Work: 0.162 
  • R-Value Observed: 0.162 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Druggable Hot Spots in the Schistosomiasis Cathepsin B1 Target Identified by Functional and Binding Mode Analysis of Potent Vinyl Sulfone Inhibitors.

Jilkova, A.Rubesova, P.Fanfrlik, J.Fajtova, P.Rezacova, P.Brynda, J.Lepsik, M.Mertlikova-Kaiserova, H.Emal, C.D.Renslo, A.R.Roush, W.R.Horn, M.Caffrey, C.R.Mares, M.

(2020) ACS Infect Dis 

  • DOI: https://doi.org/10.1021/acsinfecdis.0c00501
  • Primary Citation of Related Structures:  
    5OGQ, 5OGR

  • PubMed Abstract: 

    Schistosomiasis, a parasitic disease caused by blood flukes of the genus Schistosoma , is a global health problem with over 200 million people infected. Treatment relies on just one drug, and new chemotherapies are needed. Schistosoma mansoni cathepsin B1 (SmCB1) is a critical peptidase for the digestion of host blood proteins and a validated drug target. We screened a library of peptidomimetic vinyl sulfones against SmCB1 and identified the most potent SmCB1 inhibitors reported to date that are active in the subnanomolar range with second order rate constants ( k 2nd ) of ∼2 × 10 5 M -1 s -1 . High resolution crystal structures of the two best inhibitors in complex with SmCB1 were determined. Quantum chemical calculations of their respective binding modes identified critical hot spot interactions in the S1' and S2 subsites. The most potent inhibitor targets the S1' subsite with an N -hydroxysulfonic amide moiety and displays favorable functional properties, including bioactivity against the pathogen, selectivity for SmCB1 over human cathepsin B, and reasonable metabolic stability. Our results provide structural insights for the rational design of next-generation SmCB1 inhibitors as potential drugs to treat schistosomiasis.


  • Organizational Affiliation

    Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo n. 2, 16610 Prague, Czech Republic.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Cathepsin B-like peptidase (C01 family)
A, B, C
254Schistosoma mansoniMutation(s): 2 
Gene Names: cb1.1Smp_103610
UniProt
Find proteins for Q8MNY2 (Schistosoma mansoni)
Explore Q8MNY2 
Go to UniProtKB:  Q8MNY2
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ8MNY2
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.55 Å
  • R-Value Free: 0.203 
  • R-Value Work: 0.162 
  • R-Value Observed: 0.162 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 65.484α = 90
b = 78.072β = 91.24
c = 77.663γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XSCALEdata scaling
PDB_EXTRACTdata extraction
XDSdata reduction
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Ministry of Education, Youth and Sports of the Czech RepublicCzech RepublicLO1304
Czech Academy of SciencesCzech RepublicRVO 61388963
Ministry of Education, Youth and Sports of the Czech RepublicCzech RepublicLH15040
Ministry of Education, Youth and Sports of the Czech RepublicCzech RepublicInterBioMed LO1302

Revision History  (Full details and data files)

  • Version 1.0: 2018-11-21
    Type: Initial release
  • Version 1.1: 2020-12-30
    Changes: Database references
  • Version 1.2: 2024-01-17
    Changes: Data collection, Database references, Refinement description
  • Version 1.3: 2024-11-06
    Changes: Structure summary